Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
This study evaluates the combination chemotherapy with gemcitabine, irinotecan and panitumumab in patients with advanced biliary cancer.
Biliary Cancer|Cholangiocarcinoma
DRUG: Gemcitabine, Irinotecan, Panitumumab
Progression Free Survival Rate at Five Months, 5 months
Response Rate From Combination Chemotherapy, 5 months
This study evaluates the combination chemotherapy with gemcitabine, irinotecan and panitumumab in patients with advanced biliary cancer.